Understanding Bispecific Antibodies and Emerging Treatments at St. Louis Cancer Care

As an oncologist at St. Louis Cancer Center, I’m excited to share with our patients and their families an emerging and promising area of cancer treatment known as bispecific antibodies (BsAbs). These innovative therapies are changing the landscape of cancer treatment and bringing hope to many. 

What Are Bispecific Antibodies?

Bispecific antibodies are a type of immunotherapy that can bind to two different targets simultaneously, unlike traditional monoclonal antibodies that target only one. By binding to both cancer cells and T cells (a type of immune cell), BsAbs work as a bridge between the two, guiding the immune system to recognize and destroy the cancer cells. This targeted approach enhances the body’s natural ability to fight cancer.

How Are Bispecific Antibodies Different?

1. Targeted Action: BsAbs target specific proteins on cancer cells and T cells, bringing them together to allow T cells to effectively attack the cancer cells.

2. Dual Binding: By binding to two different targets simultaneously, BsAbs increase the precision and effectiveness of the treatment.

3. Diverse Applications: Different BsAbs can be designed to target various types of cancer, offering a more personalized approach to treatment.

St. Louis Cancer Care’s Bispecific Antibody Program

We are proud to announce that St. Louis Cancer Care is developing a program to bring these advanced treatments to our patients. One promising treatment we are currently working with is Epcoritamab, also known by its brand name Epkinly.

Epcoritamab for Diffuse Large B-Cell Lymphoma

Epcoritamab is a monoclonal antibody designed to treat diffuse large B-cell lymphoma in patients whose disease has progressed after two other treatments. It works by binding to CD3 on T cells and CD20 on B cells, guiding the immune system to target and kill cancer cells more effectively.

In clinical studies, Epcoritamab has shown significant effectiveness in treating diffuse large B-cell lymphoma. Patients who have received this treatment have experienced meaningful responses, with some achieving complete remission. This offers new hope to those who have struggled with other treatments.

Looking Ahead

As we continue to develop our program and work with innovative treatments like Epcoritamab, our goal is to provide our patients with access to the latest advances in cancer care. We believe that by integrating these cutting-edge therapies into our practice, we can offer more targeted, effective, and personalized treatment options for our patients.

We will keep you updated on our progress as we expand our bispecific antibody program. If you have any questions about this new treatment or any other aspect of your care, please feel free to contact our team at St. Louis Cancer Care. We are here to support you on your journey to better health.

Stay strong,

St. Louis Cancer Care